258 related articles for article (PubMed ID: 26735173)
1. Reactivation of wild-type and mutant p53 by tryptophanolderived oxazoloisoindolinone SLMP53-1, a novel anticancer small-molecule.
Soares J; Raimundo L; Pereira NA; Monteiro Â; Gomes S; Bessa C; Pereira C; Queiroz G; Bisio A; Fernandes J; Gomes C; Reis F; Gonçalves J; Inga A; Santos MM; Saraiva L
Oncotarget; 2016 Jan; 7(4):4326-43. PubMed ID: 26735173
[TBL] [Abstract][Full Text] [Related]
2. SLMP53-1 interacts with wild-type and mutant p53 DNA-binding domain and reactivates multiple hotspot mutations.
Gomes AS; Ramos H; Gomes S; Loureiro JB; Soares J; Barcherini V; Monti P; Fronza G; Oliveira C; Domingues L; Bastos M; Dourado DFAR; Carvalho AL; Romão MJ; Pinheiro B; Marcelo F; Carvalho A; Santos MMM; Saraiva L
Biochim Biophys Acta Gen Subj; 2020 Jan; 1864(1):129440. PubMed ID: 31536751
[TBL] [Abstract][Full Text] [Related]
3. SLMP53-1 Inhibits Tumor Cell Growth through Regulation of Glucose Metabolism and Angiogenesis in a P53-Dependent Manner.
Ramos H; Calheiros J; Almeida J; Barcherini V; Santos S; Carvalho ATP; Santos MMM; Saraiva L
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963392
[TBL] [Abstract][Full Text] [Related]
4. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
[TBL] [Abstract][Full Text] [Related]
5. A tryptophanol-derived oxazolopiperidone lactam is cytotoxic against tumors via inhibition of p53 interaction with murine double minute proteins.
Soares J; Raimundo L; Pereira NA; dos Santos DJ; Pérez M; Queiroz G; Leão M; Santos MM; Saraiva L
Pharmacol Res; 2015; 95-96():42-52. PubMed ID: 25814188
[TBL] [Abstract][Full Text] [Related]
6. Oxazoloisoindolinones with in vitro antitumor activity selectively activate a p53-pathway through potential inhibition of the p53-MDM2 interaction.
Soares J; Pereira NA; Monteiro Â; Leão M; Bessa C; Dos Santos DJ; Raimundo L; Queiroz G; Bisio A; Inga A; Pereira C; Santos MM; Saraiva L
Eur J Pharm Sci; 2015 Jan; 66():138-47. PubMed ID: 25312347
[TBL] [Abstract][Full Text] [Related]
7. SLMP53-2 Restores Wild-Type-Like Function to Mutant p53 through Hsp70: Promising Activity in Hepatocellular Carcinoma.
Gomes S; Bosco B; Loureiro JB; Ramos H; Raimundo L; Soares J; Nazareth N; Barcherini V; Domingues L; Oliveira C; Bisio A; Piazza S; Bauer MR; Brás JP; Almeida MI; Gomes C; Reis F; Fersht AR; Inga A; Santos MMM; Saraiva L
Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31405179
[TBL] [Abstract][Full Text] [Related]
8. Mutant p53 reactivator SLMP53-2 hinders ultraviolet B radiation-induced skin carcinogenesis.
Loureiro JB; Ribeiro R; Nazareth N; Ferreira T; Lopes EA; Gama A; Machuqueiro M; Alves MG; Marabini L; Oliveira PA; Santos MMM; Saraiva L
Pharmacol Res; 2022 Jan; 175():106026. PubMed ID: 34890775
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting bladder tumor growth with a cell penetrating R11 peptide derived from the p53 C-terminus.
Zhang T; Wu K; Ding C; Sun K; Guan Z; Wang X; Hsieh JT; He D; Fan J
Oncotarget; 2015 Nov; 6(35):37782-91. PubMed ID: 26462022
[TBL] [Abstract][Full Text] [Related]
10. Small-Molecule Reactivation of Mutant p53 to Wild-Type-like p53 through the p53-Hsp40 Regulatory Axis.
Hiraki M; Hwang SY; Cao S; Ramadhar TR; Byun S; Yoon KW; Lee JH; Chu K; Gurkar AU; Kolev V; Zhang J; Namba T; Murphy ME; Newman DJ; Mandinova A; Clardy J; Lee SW
Chem Biol; 2015 Sep; 22(9):1206-16. PubMed ID: 26320861
[TBL] [Abstract][Full Text] [Related]
11. Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts.
Wang W; Kim SH; El-Deiry WS
Proc Natl Acad Sci U S A; 2006 Jul; 103(29):11003-8. PubMed ID: 16835297
[TBL] [Abstract][Full Text] [Related]
12. Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro.
Burmakin M; Shi Y; Hedström E; Kogner P; Selivanova G
Clin Cancer Res; 2013 Sep; 19(18):5092-103. PubMed ID: 23864164
[TBL] [Abstract][Full Text] [Related]
13. Equivalent effect of DNA damage-induced apoptotic cell death or long-term cell cycle arrest on colon carcinoma cell proliferation and tumour growth.
Bhonde MR; Hanski ML; Notter M; Gillissen BF; Daniel PT; Zeitz M; Hanski C
Oncogene; 2006 Jan; 25(2):165-75. PubMed ID: 16170360
[TBL] [Abstract][Full Text] [Related]
14. Potency and Selectivity Optimization of Tryptophanol-Derived Oxazoloisoindolinones: Novel p53 Activators in Human Colorectal Cancer.
Barcherini V; Almeida J; Lopes EA; Wang M; Magalhães E Silva D; Mori M; Wang S; Saraiva L; Santos MMM
ChemMedChem; 2021 Jan; 16(1):250-258. PubMed ID: 32737944
[TBL] [Abstract][Full Text] [Related]
15. Adeno-associated virus-mediated survivin mutant Thr34Ala cooperates with oxaliplatin to inhibit tumor growth and angiogenesis in colon cancer.
Xue Z; Sun PH; Zhu LM; Jiang SH; Qiao MM; Chi AL; Tu SP
Oncol Rep; 2011 Apr; 25(4):1039-46. PubMed ID: 21279308
[TBL] [Abstract][Full Text] [Related]
16. Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma.
Giovannini C; Minguzzi M; Baglioni M; Fornari F; Giannone F; Ravaioli M; Cescon M; Chieco P; Bolondi L; Gramantieri L
Oncotarget; 2014 Nov; 5(21):10607-20. PubMed ID: 25431954
[TBL] [Abstract][Full Text] [Related]
17. Novel simplified yeast-based assays of regulators of p53-MDMX interaction and p53 transcriptional activity.
Leão M; Gomes S; Soares J; Bessa C; Maciel C; Ciribilli Y; Pereira C; Inga A; Saraiva L
FEBS J; 2013 Dec; 280(24):6498-507. PubMed ID: 24119020
[TBL] [Abstract][Full Text] [Related]
18. In vivo evaluation of the role of DNp73alpha protein in regulating the p53-dependent apoptotic pathway after treatment with cytotoxic drugs.
Sabatino MA; Previdi S; Broggini M
Int J Cancer; 2007 Feb; 120(3):506-13. PubMed ID: 17096333
[TBL] [Abstract][Full Text] [Related]
19. Targeting p53 for Melanoma Treatment: Counteracting Tumour Proliferation, Dissemination and Therapeutic Resistance.
Loureiro JB; Raimundo L; Calheiros J; Carvalho C; Barcherini V; Lima NR; Gomes C; Almeida MI; Alves MG; Costa JL; Santos MMM; Saraiva L
Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33916029
[TBL] [Abstract][Full Text] [Related]
20. New small molecules, ISA27 and SM13, inhibit tumour growth inducing mitochondrial effects of p53.
Sorriento D; Del Giudice C; Bertamino A; Ciccarelli M; Gomez-Monterrey I; Campiglia P; Novellino E; Illario M; Trimarco B; De Luca N; Iaccarino G
Br J Cancer; 2015 Jan; 112(1):77-85. PubMed ID: 25422906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
